EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Real-World Twelve-Month Outcomes of Switching from Aflibercept to Faricimab in Chinese Neovascular Age-Related Macular Degeneration with Inadequate Aflibercept Response

Jing Wang, Fengjiao Li, Yalin Wang iD, Xianxian Kong, Weiyan Zhou

Drug Design, Development and Therapy · 2026-11 · Volume 20 · 1-13

DOI: 10.2147/dddt.s646469 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Design, Development and Therapy, 2026-11. Verfasst von Jing Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, 250000, People's Republic…. Hauptthemen laut MEDLINE: Receptors, Vascular Endothelial Growth Factor, Recombinant Fusion Proteins, Macular Degeneration, Angiogenesis Inhibitors. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsMacular DegenerationAngiogenesis InhibitorsHumansRetrospective StudiesMaleFemaleAgedVisual AcuityTreatment OutcomeAged, 80 and overMiddle AgedChinaTime FactorsEast Asian PeopleAntibodies, Bispecific

Stichwörter der Autor:innen

afliberceptfaricimabneovascular age-related macular degenerationreal-world studysubretinal hyperreflective material

Substanzen

afliberceptReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsAngiogenesis InhibitorsfaricimabAntibodies, Bispecific

Autor:innen und Institutionen

  • Department of Ophthalmology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, 250000, People's Republic of China.

ORCID-Profile: Yalin Wang

Zitieren

APA

Wang, J., Li, F., Wang, Y., Kong, X., & Zhou, W. (2026). Real-World Twelve-Month Outcomes of Switching from Aflibercept to Faricimab in Chinese Neovascular Age-Related Macular Degeneration with Inadequate Aflibercept Response. Drug Design, Development and Therapy, Volume 20, 1-13. https://doi.org/10.2147/dddt.s646469

Vancouver

Wang J, Li F, Wang Y, Kong X, Zhou W. Real-World Twelve-Month Outcomes of Switching from Aflibercept to Faricimab in Chinese Neovascular Age-Related Macular Degeneration with Inadequate Aflibercept Response. Drug Design, Development and Therapy. 2026;Volume 20:1-13. doi:10.2147/dddt.s646469

BibTeX
@article{Wang2026,
  author = {Wang, Jing and Li, Fengjiao and Wang, Yalin and Kong, Xianxian and Zhou, Weiyan},
  title = {Real-World Twelve-Month Outcomes of Switching from Aflibercept to Faricimab in Chinese Neovascular Age-Related Macular Degeneration with Inadequate Aflibercept Response},
  journal = {Drug Design, Development and Therapy},
  year = {2026},
  volume = {Volume 20},
  pages = {1--13},
  doi = {10.2147/dddt.s646469}
}
Kostenlos starten →